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Background: FOLFOX (5-FU, Oxaliplatin and Leucovorin) is the most effective
treatment for CRC patients in adjuvant setting. However, the toxicity can lead to
reduction, delay or discontinuation of treatment. DPD is the key enzyme involved in
5-FU catabolism and 5-FU-DR is a phenotypic parameter, reflecting the entire
metabolism of 5-FU. We investigated the association between 5-FU-DR and genetic
polymorphisms of TSER, DPYD, MTHFR and with toxicity in CRC patients treated
with adjuvant FOLFOX.
Methods:We collected 126 blood samples before starting treatment. 5-FU-DR was
determined by measuring the decrease of a fixed amount of 5-FU added to a solution of
Peripheral Blood Mononuclear Cells after 2 hours of incubation. Patients were classified
as: poor metabolizers (PM: 5-FU-DR≤ 0.85 ng/ml/106cells/min); normal metabolizers
(NM: 0.85 < 5-FU-DR > 2.2 ng/ml/106cells/min); ultra-rapid metabolizers (UM:
5-FU-DR≥ 2.2 ng/ml/106cells/min). DNA pyrosequensing was used to detect gene
polymorphisms of MTHFR, DPYD and TSER. Toxicities were classified according to
CTCAE v 4.0. Statistical analysis was performed with SPSS2 software. Pearson’s Chi
Square test was used to correlate gene polymorphisms and 5-FU-DR with toxicities.
Results:We analyzed 126 resected CRC patients (91 M, 35 F; median age 65 y, range
36-81 y), receiving adjuvant FOLFOX. 7 patients were PM, 116 NM and 3 UM. Median
5-FU-DR was 1.495 ng/ml/106cells/min (range 0.42-2.29). G3-4 toxicities were
observed in 22.2% of the cases: 59.3% hematological, 29.6% gastrointestinal, 7.4%
neurological and 3.7% others. A higher G3-4 toxicity incidence was observed in PM
and UM than in NM group (71.4% and 33.3% respectively vs 19%; p = 0.05). PM and
UM required more frequently dose reduction due to toxicity (71.4% and 66.6% vs 31%;
p = 0.04). One case of DPYD heterozygous mutated was detected and it was associated
with 5-FU-DR PM (p = 0.04) and G4 hematological toxicity (p = 0.06). No statistically
significant associations between toxicities and TSER (p = 0.2), MTHFR C677T
(p = 0.5) and MTHFR A1298C (p = 0.8) were observed.
Conclusions: 5-FU-DR seems to predict toxicity in resected CRC patients treated with
5-FU. Larger and perspective studies are required to implement this results.
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